CAJ | 학술논문

目的评价小剂量普萘洛尔治疗小儿腮腺血管瘤的临床疗效和安全性.方法 17例婴幼儿血管瘤患者按1.0～1.5 mg/kg体重13服普萘洛尔,每日1次,连续服用3～5个月.每周复诊,动态观察和记录血管瘤大小、质地、颜色的变化,并随时处理治疗过程中出现的不良反应.按4级评分法对近期疗效进行评价.结果 17例随访3～10个月,疗效:I级0例,Ⅱ级:0例,Ⅲ级:5例,Ⅳ级:12例.17例均未发生严重不良反应.结论口服小剂量普萘洛尔治疗婴幼儿增生期腮腺血管瘤近期疗效好,不良反应轻微,普萘洛尔可作为婴幼儿腮腺血管瘤的一线治疗药物.
목적 평개소제량보내락이치료소인시선혈관류적림상료효화안전성.방법 17례영유인혈관류환자안1.0～1.5 mg/kg체중13복보내락이,매일1차,련속복용3～5개월.매주복진,동태관찰화기록혈관류대소、질지、안색적변화,병수시처리치료과정중출현적불량반응.안4급평분법대근기료효진행평개.결과 17례수방3～10개월,료효:I급0례,Ⅱ급:0례,Ⅲ급:5례,Ⅳ급:12례.17례균미발생엄중불량반응.결론 구복소제량보내락이치료영유인증생기시선혈관류근기료효호,불량반응경미,보내락이가작위영유인시선혈관류적일선치료약물.
Objective To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma.Methods Oral propranolol was administered to 17 infants with parotid heamngiom at a dose of 1.0-1.5 mg per kilogram of body weight per day.The patients were revisited once a week.The changes of the tumor size, texture and colour were monitored and recorded at a regular interval.The adverse effects after medication were observed and managed accordingly.The short-term results were evaluated using a 4 scales system.Results Among the 17 patients treated, the follow-up time was 5 to 10 months.The overall response was scale I in 0 patient, scale Ⅱ in 0 patients, scale Ⅲ in 5 patients, and scale Ⅳ in 12 patients.No serious adverse effects were encountered.Conclusions Oral propranolol at a lower dose is a safe and effective method for the treatment of infantile parotid heamngioma.The short-term results were excellent and the side effects minimal.